We enrolled 50 patients with MCL in this single-institution, single-arm, phase II clinical trial (NCT01880567). Patients with Ki-67% ≥ 50% and blastoid morphology were excluded. Ibrutinib was ...
Brexucabtagene autoleucel approval marked a significant advancement in MCL treatment, achieving a 62% complete remission rate in resistant or relapsed patients. Prognostic tools like the Ki-67 index ...
Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms Patients with cBTKi pretreated relapsed/refractory (R/R) MCL received pirtobrutinib monotherapy in a multicenter ...
Anita Kumar, MD, medical oncologist with Memorial Sloan Kettering Cancer Center, led a session at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), on New Directions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results